Evidence map›Paper›PMID 30618085›Full record

ReviewStem cells translational medicine2019

Concise Review: Therapeutic Potential of the Mesenchymal Stem Cell Derived Secretome and Extracellular Vesicles for Radiation-Induced Lung Injury: Progress and Hypotheses.

Siguang Xu, Cong Liu, Hong-Long Ji

Open access · goldAbstract readReview
In one paragraph

Review in Stem cells translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 95 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Regenerative Signatures in BAL of Acute Respiratory Distress Syndrome.American journal of respiratory cell and molecular biology · 2024
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Siguang XuInstitute of Lung and Molecular Therapy, Xinxiang Medical University, Xinxiang, Henan, People's Republic of China.ORCID 0000-0002-2010-1111
Cong LiuInstitute of Lung and Molecular Therapy, Xinxiang Medical University, Xinxiang, Henan, People's Republic of China.
Hong-Long JiDepartment of Cellular and Molecular Biology, University of Texas Health Science Center at Tyler, Tyler, Texas, USA.ORCID 0000-0002-3228-7144
Xinxiang Medical University · CNThe University of Texas Health Science Center at Tyler · US

Funding

NOVEL PARACRINE MECHANISMS FOR CELL-BASED THERAPY OF INJURED LUNGSR01HL134828 · NHLBI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI JI, HONG-LONG · 2017 to 2025
$3.4M
NHLBI NIH HHS R01 HL134828
6 · The paper itself

Abstract

Radiation-induced lung injury (RILI) is a common complication in radiotherapy of thoracic tumors and limits the therapeutic dose of radiation that can be given to effectively control tumors. RILI develops through a complex pathological process, resulting in induction and activation of various cytokines, infiltration by inflammatory cells, cytokine-induced activation of fibroblasts, and subsequent tissue remodeling by activated fibroblasts, ultimately leading to impaired lung function and respiratory failure. Increasing evidence shows that mesenchymal stem cells (MSCs) may play a main role in modulating inflammation and immune responses, promoting survival and repair of damaged resident cells and enhancing regeneration of damaged tissue through soluble paracrine factors and therapeutic extracellular vesicles. Therefore, the use of the MSC-derived secretome and exosomes holds promising potential for RILI therapy. Here, we review recent progress on the potential mechanisms of MSC therapy for RILI, with an emphasis on soluble paracrine factors of MSCs. Hypotheses on how MSC derived exosomes or MSC-released exosomal miRNAs could attenuate RILI are also proposed. Problems and translational challenges of the therapies based on the MSC-derived secretome and exosomes are further summarized and underline the need for caution on rapid clinical translation. Stem Cells Translational Medicine 2019;8:344-354.

Indexed as

AnimalsDisease ProgressionExosomesExtracellular VesiclesHumansLung InjuryMesenchymal Stem CellsRadiation InjuriesRegenerationExosomeLung fibrosisMesenchymal stem cellsRadiation pneumonitisSecretome

Identifiers

PMID30618085
PMCPMC6431606
OpenAlexW2910305379

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.